Business
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks earlier than standard-of-care
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nNew Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks earlier than standard-of-care RECIST methods1-11\n\n\n\nNew Guardant360 TissueNext™ tissue biopsy test is now available for ordering alongside the Guardant360® CDx blood test, providing oncologists an efficient “blood-first, tissue-next” approach for complete genomic testing\n\n\n REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment. The Guardant360 TissueNext™ test, the company’s first tissue-based test, is now available, if needed, to help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment.\n\nBoth products expand on the trusted Guardant360® portfolio to offer oncologists end-to-end testing solutions, covering treatment selection, with the option of ordering tissue biopsy results if needed, and treatment response monitoring, to help improve clinical outcomes for patients with advanced cancer.\n\nThe Guardant360 Response liquid biopsy test detects changes in ctDNA levels from a simple blood draw, to assess treatment response up to eight weeks earlier than RECIST (Response Evaluation Criteria in Solid Tumors),1-11 giving oncologists a new tool to use when considering whether to continue, stop, or explore other treatment options for their patients with late-stage or metastatic cancer. Molecular responders (those with decreasing ctDNA levels) show significantly longer progression-free and overall survival rates, compared to molecular non-responders.1-12 In over 50 studies, Guardant Health has demonstrated that molecular response, as measured by changes in ctDNA levels, can help provide an early indication of treatment response across therapies (targeted, immunotherapy, and chemotherapy) and cancer types including non-small cell lung, colorectal, breast, and bladder.1-12\n\n“Using circulating tumor DNA levels to monitor treatment response is a promising ne...